2. Search Result
Search Result
Results for "

Caki-1

" in MedChemExpress (MCE) Product Catalog:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-123611
    Supinoxin

    RX-5902

    		 DNA/RNA Synthesis Apoptosis Cancer
    Supinoxin (RX-5902) is an orally active inhibitor of phosphorylated-p68 RNA helicase (P-p68) and a potent first-in-class anti-cancer agent. Supinoxin interacts with Y593 phosphorylated-p68 and attenuates the nuclear shuttling of β-catenin. Supinoxin induces cell apoptosis and inhibits growth of TNBC cancer cell lines with IC50s ranging from 10 nM to 20 nM [1] .
    Supinoxin
  • HY-15004
    AUZ 454
    5+ Cited Publications

    K03861

    		 CDK Cancer
    AUZ 454 (K03861) is a type II CDK2 inhibitor with Kd of 8.2 nM. AUZ 454 (K03861) inhibits CDK2 activity by competing with binding of activating cyclins.
    AUZ 454
  • HY-13691
    MKC-1

    Ro-31-7453

    		 Apoptosis Akt mTOR Microtubule/Tubulin Mitosis Cancer
    MKC-1 (Ro-31-7453) is an orally active and potent cell cycle inhibitor with broad antitumor activity. MKC-1 inhibits the Akt/mTOR pathway. MKC-1 arrests cellular mitosis and induces cell apoptosis by binding to a number of different cellular proteins including tubulin and members of the importin β family [1] .
    MKC-1
  • HY-157231A
    HC-5404-Fu

    		PERK Cancer
    HC-5404-Fu is an orally active PERK inhibitor with an IC50 of 0.001 μM against human PERK. HC-5404-Fu blocks PERK activation induced by VEGFR-TKI and disrupts the adaptive stress response triggered by VEGFR-TKI. HC-5404-Fu enhances anti-angiogenic effects by inhibiting newly formed and mature tumor blood vessels in renal cell carcinoma models. HC-5404-Fu can be used in research related to renal cell carcinoma [1].
    HC-5404-Fu
  • HY-161865
    Antitumor agent-180

    		Apoptosis Cancer
    Antitumor agent-180 (Compound 13a) is an inhibitor for BUB1 mitotic checkpoint serine/threonine kinase B (BUB1B). Antitumor agent-180 inhibits the proliferation of ccRCC cell Caki-1 with IC50 of 2.047 µM. Antitumor agent-180 induces necrosis and apoptosis in Caki-1 [1].
    Antitumor agent-180
  • HY-172089
    TG101209 analog 1

    		Apoptosis Cancer
    TG101209 analog 1 (Compound 8h) is an inhibitor for BUB1B with an IC50 of 10.36 μM. TG101209 analog 1 exhibits cytotoxicity (IC50 for Caki-1 is 1.347 μM), induce necrosis and apoptosis [1].
    TG101209 analog 1
  • HY-158046
    UNC8899

    		PROTACs STING Infection
    UNC8899 is a VHL-recruiting STING PROTAC degrader (DC50: 0.0.924 μM). UNC8899 can be used for viral or bacterial infection research (Blue: VHL ligand, Black: linker; Pink: STING inhibitor) [1].
    UNC8899
  • HY-13691R
    MKC-1 (Standard)

    Ro-31-7453 (Standard)

    		 Apoptosis Akt mTOR Microtubule/Tubulin Mitosis Reference Standards Cancer
    MKC-1 (Standard) is the analytical standard of MKC-1. This product is intended for research and analytical applications. MKC-1 (Ro-31-7453) is an orally active and potent cell cycle inhibitor with broad antitumor activity. MKC-1 inhibits the Akt/mTOR pathway. MKC-1 arrests cellular mitosis and induces cell apoptosis by binding to a number of different cellular proteins including tubulin and members of the importin β family [1] .
    MKC-1 (Standard)
  • HY-146230
    VEGFR-2-IN-26

    		VEGFR Cancer
    VEGFR-2-IN-26 (compound 5h) is a highly potent VEGFR-2 inhibitor with an IC50 value of 15.5 nM. VEGFR-2-IN-26 has good antiproliferative activity against the leukemic, non-small lung, CNS, ovarian, renal, prostate and breast cancer cells [1].
    VEGFR-2-IN-26
  • HY-W470101
    HIF-2α-IN-17

    		HIF/HIF Prolyl-Hydroxylase Apoptosis HSP Caspase Cancer
    HIF-2α-IN-17 is a selective hypoxia-inducible factor 2α (HIF2α) inhibitor that binds to the PAS-B domain of HIF2α. HIF-2α-IN-17 disrupts the interaction between HIF2α and the molecular chaperone Hsp70, leading to proteasomal degradation of HIF2α. HIF-2α-IN-17 exhibits antitumor activity and induces apoptosis in cancer cells. HIF-2α-IN-17 is applicable for research on cancers such as clear cell renal cell carcinoma [1].
    HIF-2α-IN-17

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: